DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Johanna Geron - 1 Velsipity - 1 Bristol Myers - 1 Khushi - 1 Arun Koyyur - 1
Top related locs:
Puurs Belgium U.S United States Bengaluru
Top related orgs:
Pfizer - 1 REUTERS - 1 U.S . Food - 1 Drug Administration - 1 Arena Pharmaceuticals - 1 Bristol - 1 drugmakers - 1 Thomson - 1

Search resuls for: "Arena Pharmaceuticals"


5 mentions found


☆ US FDA approves Pfizer's inflammatory bowel disease drug
  + stars: | 2023-10-13 | by ( ) www.reuters.com   time to read: +1 min
REUTERS/Johanna Geron/File Photo Acquire Licensing RightsOct 13 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer's (PFE.N) drug to treat adults with an inflammatory bowel disease called ulcerative colitis, the company said on Friday. The decision was based on data from a late-stage study that showed a reduction in disease symptoms for some patients who took the drug, when compared with the placebo. Globally, the market for inflammatory bowel diseases is about $20 billion, making it a lucrative target for drugmakers. Analysts last year estimated that peak sales for the Pfizer drug could top $3 billion a year. Reporting by Khushi Mandowara in Bengaluru; Editing by Arun Koyyur and Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.
Persons: Johanna Geron, Velsipity, Bristol Myers, Khushi, Arun Koyyur Organizations: Pfizer, REUTERS, U.S . Food, Drug Administration, Arena Pharmaceuticals, Bristol, drugmakers, Thomson Locations: Puurs, Belgium, U.S, United States, Bengaluru
☆ Pfizer looks past COVID with $43 bln deal for cancer drug innovator Seagen
  + stars: | 2023-03-13 | by ( Manas Mishra Michael Erman | Manas Mishra | Michael Erman | ) www.reuters.com   time to read: +3 min
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed for a targeted destructive effect and spare healthy cells. The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. The drugmaker expects more than $10 billion in sales from Seagen products in 2030, and another $15 billion from its other recent acquisitions. Pfizer said antitrust regulators could closely review the deal due to its size but eventually approve it. Pfizer rival Merck & Co Inc (MRK.N) and Seagen were in advanced deal talks last year but those reportedly collapsed over antitrust concerns.
☆ The Covid sales boom is over for Pfizer
  + stars: | 2023-01-31 | by ( Paul R. La Monica | ) edition.cnn.com   time to read: +3 min
New York CNN —Pfizer generated nearly $57 billion in combined sales last year from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill. Pfizer (PFE) told Wall Street Tuesday that it expects Covid-related sales to plunge to $21.5 billion this year… below Wall Street’s forecasts. Pfizer noted that it now expects to sell just $13.5 billion of its vaccine and $8 billion of the Paxlovid pill this year. Wall Street was expecting vaccine revenue of $14.4 billion and $10.3 billion of Paxlovid for 2023, according to estimates tracked by Refinitiv. Pfizer reported Comirnaty sales of $37.8 billion last year and revenue of $18.9 billion from Paxlovid.
☆ Jim Cramer recommends these 5 healthcare stocks in 2023
  + stars: | 2022-12-15 | by ( Krystal Hur | ) www.cnbc.com   time to read: +1 min
CNBC's Jim Cramer on Thursday presented investors with a roster of healthcare stocks that should be on their shopping lists for next year. "Wall Street likes profitable companies with consistent results, nice dividends and reasonably-valued stocks," he said, adding, "The biggest [healthcare] winners were boring, consistent operators with cheap stocks." Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks – in other words, they perform well regardless of the state of the economy. UnitedHealth GroupCramer said that he likes the "best-of-breed" managed healthcare stock. Edwards LifesciencesCramer says he likes the stock because the company's underlying business has been strong, despite the stock being down over 43% for the year.
☆ Roivant, Pfizer team up on inflammatory disease drug
  + stars: | 2022-12-01 | by ( Bhanvi Satija Khushi Mandowara | Bhanvi Satija | Khushi Mandowara | ) www.reuters.com   time to read: +2 min
Dec 1 (Reuters) - Biotech firm Roivant Sciences (ROIV.O) on Thursday launched a company with Pfizer Inc (PFE.N) focused on an experimental bowel disease treatment, as the drugmakers seek to tap into a multibillion dollar market. The drug, RVT-3101, was originally developed by Pfizer, which will hold a 25% stake in the new business, with Roivant holding the majority interest. SVB Securities analyst David Risinger says the deal shows how Pfizer is prioritizing research spending for its oral ulcerative colitis drug, etrasimod, which holds a near-term blockbuster opportunity. RVT-3101 could represent a nearly $15 billion commercial opportunity in the United States for Roivant as a treatment for both ulcerative colitis and Crohn’s disease, said Risinger. Pfizer has also licensed its inflammatory autoimmune disease drug brepocitinib to Roivant in exchange for a 25% stake in another jointly held company called Priovant.
0 next >>
Total: 5